Given the robust protection against diabetes development observed with T cell loss of BCL6 despite persistence of insulin-binding B cells in the periphery, our findings highlight the translational potential of BCL6 inhibition in T1D, even at a point when B cell autoimmunity for insulin has already manifested, such as in Stage 1 T1D, which will require clinical trial confirmation. Here, BCL6 is linked to diabetes mellitus.